ALSO NOTED: Avanir selling $16M in shares; Genaera reports positive prelim data; 5T4 antibody-targeted therapy advances; and mu

> Avanir Pharmaceuticals plans to sell $16.15 million of its shares to a select group of buyers. Release

> Genaera said that it recorded positive preliminary data from a Phase II trial of Evizon with concomitant photodynamic therapy with Visudyne in 45 subjects with wet age-related macular degeneration. Release

> Oxford BioMedica said company licensee Wyeth reported significant preclinical results for its 5T4 antibody-targeted therapy for the treatment of solid tumors. Release

> Beijing Med-Pharm has raised $6.3 million in a private placement. Release

And Finally... Indian officials have inked a pact with Johns Hopkins for the exchange of data and collaborative projects on biotechnology and nanotechnology. Article